Results 131 to 140 of about 13,727 (197)

Sacubitril/valsartan in heart failure: a critical look at dementia risk and future study pathways. [PDF]

Eur Heart J Cardiovasc Pharmacother
Dong W, Li W.
europepmc   +1 more source

Effects of sacubitril/valsartan on ventricular remodeling in patients with hypertension and maintenance hemodialysis: a retrospective cohort study. [PDF]

Front Cardiovasc Med
Jiang L, Min X, Ran J, Zhu Y, Pan L, Yang B, Ran X, Ran Y, Ding H, Yang J, Wu S.   +10 more
europepmc   +1 more source

Impact of Sacubitril/Valsartan on Cardiac Autonomic Function Assessed Using Physiological Data from Implantable Cardioverter-Defibrillators. [PDF]

J Clin Med
Barone L, Sergi D, Maglia G, Bontempi L, Giaccardi M, Baroni M, Amellone C, Curnis A, D'Alterio G, Saporito D, Vinciguerra P, Cipani S, Mazzone P, Giammaria M, Mitacchione G, Masarone D, Fabbri F, Vannelli A, Baldassarre I, Del Maestro M, Giacopelli D, Celentano E, Zanotto G, Barillà F.   +23 more
europepmc   +1 more source

Impact of Sacubitril/Valsartan on Cardiac Reverse Remodeling in Patients with Heart Failure Undergoing Cardiac Resynchronization Therapy. [PDF]

Diseases
Atabekov T, Silivanova I, Kisteneva I, Krivolapov S, Batalov R, Popov S.   +5 more
europepmc   +1 more source

Efficacy of Sacubitril/Valsartan Among Heart Failure Individuals With Implanted Cardiac Defibrillators: A Systematic Review and Meta-Analysis. [PDF]

J Arrhythm
Asham H, Salehian S, Gharekhani A, Safaei N, Sarbakhsh P, Entezari-Maleki T.   +5 more
europepmc   +1 more source

Hyperkalaemia szívelégtelenségben. Új kezelési lehetőségek a láthatáron = Hyperkalemia in heart failure. New treatments on the horizon [PDF]

, 2018
Dékány, Miklós, Kiss, Róbert Gábor, Nyolczas, Noémi, Szabó, Márta, Vágány, Dénes   +4 more
core   +1 more source

Differential cardiovascular benefits of SGLT2 inhibitors, sacubitril/valsartan, omecamtiv mecarbil, and vericiguat across heart failure phenotypes: a systematic review and meta-analysis. [PDF]

Front Pharmacol
Wang M, Zuo Z, Wu T, Zhou Z.
europepmc   +1 more source

Bleeding Disorder, A Newly Recognized Adverse Event Following Sacubitril/Valsartan Therapy. [PDF]

Eur J Case Rep Intern Med
Al-Omari YW, Mustafa SA, Saleh AH, Abdel-Razaq WS.   +3 more
europepmc   +1 more source

Efficacy and safety of sacubitril/valsartan combined with dapagliflozin in non-diabetic patients with advanced chronic kidney disease. [PDF]

Front Endocrinol (Lausanne)
Wang H, Li X, Jiang C, Liu X.
europepmc   +1 more source

The Effect of Sacubitril/Valsartan on Mood and Cognitive Function in Patients with Heart Failure with Reduced Ejection Fraction. [PDF]

Brain Sci
Al Kindi F, Al Maskari R, Al Mahruqi F, Al Riyami A, Al Yarabi Z, Kaddoura R, Al Busaidi M, Al Adawi S.   +7 more
europepmc   +1 more source